Last Update 07 Mar 26

Fair value Increased 14%

LXRX: Phase 3 Pain Program And Partnership Prospects Will Support Future Upside

Analysts have raised their price targets on Lexicon Pharmaceuticals, with one moving from $4 to $6, citing a higher assumed probability of success for pilavapadin and the potential for an important partnership on this Phase 3 ready program.

Analyst Commentary

Bullish Takeaways

Bullish analysts see the higher assumed probability of success for pilavapadin, at 30% versus the prior 15%, as a key input to higher valuation for Lexicon, particularly as the program is described as Phase 3 ready.
The expectation of an important partnership around pilavapadin signals potential external validation of the asset and could help fund later stage development, which matters for execution on the current pipeline.
Recent commentary credits Lexicon's clinical and regulatory work with helping to reduce perceived program risk, which supports more constructive views on execution and long term growth potential if pilavapadin progresses as planned.
The move in price targets from US$4 to US$6 reflects increased confidence in the risk adjusted contribution of pilavapadin to Lexicon's overall equity value, even though outcomes are still tied to future trial and deal progress.

Bearish Takeaways

More cautious analysts may focus on the fact that, even at a 30% probability of success, pilavapadin still carries significant development risk, so valuation remains sensitive to clinical and regulatory outcomes.
Expectations for an important partnership introduce execution risk, as the timing and structure of any deal, including potential upfront or milestone payments, remain uncertain.
With price targets now anchored partly on a Phase 3 ready asset, any delays, setbacks, or changes in regulatory feedback around pilavapadin could weigh on sentiment and future target revisions.
The emphasis on a single late stage program highlights concentration risk for Lexicon's growth story, which some investors may view as a constraint until there is broader pipeline or revenue diversification.

What's in the News

Lexicon closed a private placement on February 2, 2026, issuing 22,400,000 common shares at US$1.30 per share for gross proceeds of US$29,120,000 and 367,145 Series B convertible preferred shares at US$65 per share for gross proceeds of US$23,864,425, for total gross proceeds of US$52,984,425 from one accredited investor under Regulation D (Key Developments).
The company completed a follow on equity offering of common stock totaling US$41.6m, issuing 32,000,000 shares at a price of US$1.30 per share, with a stated discount of US$0.078 per share (Key Developments).
Lexicon filed a follow on equity offering of common stock ahead of the completed US$41.6m raise, indicating additional equity issuance activity around the same period (Key Developments).
Following an End of Phase 2 meeting, the U.S. FDA raised no objections to advancing pilavapadin into Phase 3 for diabetic peripheral neuropathic pain. The plan is for two placebo controlled, 12 week registrational studies using change in average daily pain score at Week 12 as the primary endpoint (Key Developments).
Lexicon has been removed from the NASDAQ Biotechnology Index, which may affect index fund and ETF ownership tied to that benchmark (Key Developments).

Valuation Changes

Fair Value: $2.92 to $3.32, indicating a modest upward reset in the modelled per share value.
Discount Rate: 6.978% unchanged, indicating no revision to the risk or return assumptions used in the model.
Revenue Growth: the previous assumption of a 10.87% decline has been revised to 4.32% growth, reflecting a meaningful swing in the top line outlook.
Net Profit Margin: 20.42% to 21.47%, showing a small improvement in projected profitability.
Future P/E: 126.98x to 121.89x, indicating a slight reduction in the earnings multiple applied to future profits.

2 views

Key Takeaways

Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.
Strategic licensing and cost reduction initiatives aim to boost revenue streams while improving net margins and profitability.
Strategic partnerships and increased R&D investments introduce dependency risks and elevate costs, affecting Lexicon's financial stability, revenue potential, and market opportunities.

Catalysts

About Lexicon Pharmaceuticals

A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.What are the underlying business or industry changes driving this perspective?

Lexicon Pharmaceuticals is focused on advancing its pipeline of novel medicines, including progressing pilavapadin into pivotal trials as a first novel oral non-opioid treatment for diabetic peripheral neuropathic pain in over two decades, which could significantly impact future revenue growth and market share.
The company is developing LX9851, a first-in-class oral ACSL5 inhibitor for obesity and related cardiometabolic disorders, with promising preclinical data, which could open new revenue streams and target high-demand markets once the IND is submitted in 2025.
The strategic licensing agreement with Viatris for sotagliflozin outside the U.S. and Europe provides a financial catalyst by reducing operational burden while ensuring revenue through licensing fees and potential royalties.
Sotagliflozin's ongoing pivotal Phase III SONATA-HCM study could lead to expanded label indications for hypertrophic cardiomyopathy, potentially increasing market penetration and future earnings if approved.
Cost reduction initiatives, such as ceasing INPEFA promotion and employee restructuring, anticipate reduced operating expenses going forward, improving net margins and potentially enhancing future profitability.

Lexicon Pharmaceuticals Earnings and Revenue Growth

Lexicon Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Lexicon Pharmaceuticals's revenue will grow by 10.7% annually over the next 3 years.
Analysts are not forecasting that Lexicon Pharmaceuticals will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Lexicon Pharmaceuticals's profit margin will increase from -644.8% to the average US Biotechs industry of 15.9% in 3 years.
If Lexicon Pharmaceuticals's profit margin were to converge on the industry average, you could expect earnings to reach $6.7 million (and earnings per share of $0.02) by about May 2028, up from $-200.4 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 211.2x on those 2028 earnings, up from -1.2x today. This future PE is greater than the current PE for the US Biotechs industry at 20.4x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.14%, as per the Simply Wall St company report.

Lexicon Pharmaceuticals Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Lexicon Pharmaceuticals relies on strategic repositioning and partnerships to advance its clinical programs, which introduces dependency risks and potential delays, potentially affecting future revenues and market opportunities.
The company ceased promotional efforts for INPEFA in the U.S. due to a difficult market access environment, reflecting challenges in generating significant revenue from this asset and indicating competitive pressures that may affect earnings.
There was an increase in R&D expenses due to investments in clinical trials, leading to elevated operating costs which could impact net margins, especially if these programs do not yield successful outcomes or commercial products.
Lexicon reported a net loss for 2024, which, despite revenue from a new licensing agreement, highlights financial challenges and the risk of not achieving profitability, impacting overall financial stability and sustainability.
The ongoing need for additional pivotal trials and regulatory approvals for its pipeline suggests potential high costs and risks in drug development, which could strain financial resources and impact future earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $2.6 for Lexicon Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $6.0, and the most bearish reporting a price target of just $0.8.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $42.2 million, earnings will come to $6.7 million, and it would be trading on a PE ratio of 211.2x, assuming you use a discount rate of 7.1%.
Given the current share price of $0.67, the analyst price target of $2.6 is 74.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Lexicon Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Pilavapadin Trials And LX9851 Development Will Expand Treatment Options